Drug therapy in the hepatic patient

It is confirmed that the effect of drugs in the body does not vary with the same intensity in hepatopathies as it does in nephropathies; this is attributed to the genetic constitution of each individual and the induction of the microsomal enzymatic systems. It has been observed both in hepatopathies with a deficient conjugation of bilirubin as well as in acquired hepatopathies that there are significant differences for certain drugs. As regards acquired hepatopathies, the data available indicate that the pathway most profoundly affected is acetylation, thereby affecting drugs, which are actylated in the liver; other pathways and conjugations will be less severely affected.